<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: development", fill: "#5d8aa8"},
{source: "1: development", target: "1: activities", fill: "#5d8aa8"},
{source: "1: development", target: "6: activities will", fill: "#48d1cc"},
{source: "6: activities will", target: "6: foreseeable future", fill: "#48d1cc"},
{source: "6: foreseeable future", target: "6: commercialize", fill: "#48d1cc"},
{source: "6: activities will", target: "11: Development of Our Products ", fill: "#bdda57"},
{source: "11: Development of Our Products ", target: "11: Early Stage ", fill: "#bdda57"},
{source: "11: Early Stage ", target: "11: proposed products", fill: "#bdda57"},
{source: "11: proposed products", target: "11: early stage", fill: "#bdda57"},
{source: "11: early stage", target: "11: clinical development", fill: "#bdda57"},
{source: "11: clinical development", target: "11: significant timeconsuming", fill: "#bdda57"},
{source: "11: significant timeconsuming", target: "11: development testing", fill: "#bdda57"},
{source: "11: development testing", target: "11: regulatory clearances", fill: "#bdda57"},
{source: "11: Development of Our Products ", target: "14: proposed products will", fill: "#4d5d53"},
{source: "14: proposed products will", target: "14: manufacture", fill: "#4d5d53"},
{source: "14: manufacture", target: "14: market acceptance", fill: "#4d5d53"},
{source: "14: proposed products will", target: "17: product candidates", fill: "#253529"},
{source: "17: product candidates", target: "17: preclinical stages", fill: "#253529"},
{source: "17: preclinical stages", target: "17: development", fill: "#253529"},
{source: "17: product candidates", target: "21: regulatory", fill: "#fad6a5"},
{source: "21: regulatory", target: "21: product candidates will", fill: "#fad6a5"},
{source: "21: product candidates will", target: "21: subsequent sale", fill: "#fad6a5"},
{source: "21: subsequent sale", target: "21: completion", fill: "#fad6a5"},
{source: "21: completion", target: "21: clinical trials", fill: "#fad6a5"},
{source: "21: regulatory", target: "25: following factors among", fill: "#f3e5ab"},
{source: "25: following factors among", target: "25: others could", fill: "#f3e5ab"},
{source: "25: others could", target: "25: additional funds", fill: "#f3e5ab"},
{source: "25: additional funds", target: "25: cash requirements", fill: "#f3e5ab"},
{source: "25: cash requirements", target: "25: increase materially", fill: "#f3e5ab"},
{source: "25: increase materially", target: "25: development activities", fill: "#f3e5ab"},
{source: "25: development activities", target: "25: preclinical studies", fill: "#f3e5ab"},
{source: "25: preclinical studies", target: "25: clinical trials", fill: "#f3e5ab"},
{source: "25: clinical trials", target: "25: terminations", fill: "#f3e5ab"},
{source: "25: terminations", target: "25: relationships with strategic", fill: "#f3e5ab"},
{source: "25: relationships with strategic", target: "25: focus direction", fill: "#f3e5ab"},
{source: "25: focus direction", target: "25: development programs", fill: "#f3e5ab"},
{source: "25: development programs", target: "25: competitive", fill: "#f3e5ab"},
{source: "25: competitive", target: "25: technological advances", fill: "#f3e5ab"},
{source: "25: technological advances", target: "25: establishment", fill: "#f3e5ab"},
{source: "25: establishment", target: "25: sales capabilities", fill: "#f3e5ab"},
{source: "25: sales capabilities", target: "25: manufacturing", fill: "#f3e5ab"},
{source: "25: manufacturing", target: "25: regulatory approval process", fill: "#f3e5ab"},
{source: "25: regulatory approval process", target: "25: product launch", fill: "#f3e5ab"},
{source: "25: following factors among", target: "START_HERE", fill: "#f3e5ab"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_development">Human development</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_development">Business development</a></td>
      <td>Business development entails tasks and processes to develop and implement growth opportunities within and between organizations. It is a subset of the fields of business, commerce and organizational theory.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Notepad">Windows Notepad</a></td>
      <td>Windows Notepad is a simple text editor for Windows; it creates and edits plain text documents. First released in 1983 to commercialize the computer mouse in MS-DOS, Notepad has been part of every version of Windows ever since.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_engineering">Manufacturing engineering</a></td>
      <td>Manufacturing engineering is a branch of professional engineering that shares many common concepts and ideas with other fields of engineering such as mechanical, chemical, electrical, and industrial engineering. \nManufacturing engineering requires the ability to plan the practices of manufacturing; to research and to develop tools, processes, machines and equipment; and to integrate the facilities and systems for producing quality products with the optimum expenditure of capital.The manufacturing or production engineer's primary focus is to turn raw material into an updated or new product in the most effective, efficient &amp; economic way possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bally_Manufacturing">Bally Manufacturing</a></td>
      <td>Bally Manufacturing, later renamed Bally Entertainment, was an American company that began as a pinball and slot machine manufacturer, and later expanded into casinos, video games, health clubs, and theme parks. It was acquired by Hilton Hotels in 1996.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ENTREMED INC      ITEM 1A   RISK FACTORS     We Have a History of Losses and Anticipate Future Losses          To date, we have been engaged primarily in research and <font color="blue">development</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  have received <font color="blue">license fees</font> and research and     <font color="blue">development</font>  funding  from  a <font color="blue">former collaborator</font>, limited revenues on     <font color="blue">royalties from sales</font> of Thalomid^® and certain research grants, we have not     derived <font color="blue">significant</font> <font color="blue">revenues from</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">At <font color="blue">December </font></font>31, 2005, we had an <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font>     dlra261cmam747cmam800</td>
    </tr>
    <tr>
      <td>Losses have <font color="blue">continued since</font> <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We will also be     required  to conduct substantial research and <font color="blue">development</font> and clinical     testing  <font color="blue">activities</font>  for  our  <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>We expect that these     <font color="blue">activities</font> will result in operating losses for the <font color="blue">foreseeable future</font> before     we <font color="blue">commercialize</font> any products, if ever</td>
    </tr>
    <tr>
      <td>In addition, to the extent we rely     on others to develop and <font color="blue">commercialize</font> our products, our ability to achieve     <font color="blue">profitability</font>  <font color="blue">will depend upon</font> the success of these other parties</td>
    </tr>
    <tr>
      <td>To     support our research and <font color="blue">development</font> of <font color="blue">certain <font color="blue">product <font color="blue">candidates</font></font></font>, we also     <font color="blue"><font color="blue">may rely on</font> <font color="blue">cooperative <font color="blue">agreements</font></font> from governmental</font> and other <font color="blue">organizations</font>     as a source of support</td>
    </tr>
    <tr>
      <td>If our <font color="blue">cooperative <font color="blue">agreements</font></font> were to be reduced to     any substantial extent, it may impair our ability to continue our research     and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>Even if we do achieve <font color="blue">profitability</font>, we may be     unable to sustain or increase it</td>
    </tr>
    <tr>
      <td><font color="blue">Development of Our Products </font>is at an <font color="blue">Early Stage </font>and is Uncertain          Our <font color="blue">proposed products</font> and research programs are in the <font color="blue">early stage</font> of     clinical <font color="blue">development</font> and require <font color="blue">significant</font>, time-consuming and costly     research and <font color="blue">development</font>, testing and <font color="blue"><font color="blue">regulatory</font> <font color="blue">clearances</font></font></td>
    </tr>
    <tr>
      <td>In developing     our products, we are subject to risks of failure that are inherent in the     <font color="blue">development</font> of products and <font color="blue">therapeutic procedures</font></td>
    </tr>
    <tr>
      <td>For example, it is     possible that any or all of our <font color="blue">proposed products</font> will be <font color="blue">in<font color="blue">effective</font></font> or     toxic, or <font color="blue">otherwise will fail</font> to receive <font color="blue">necessary</font> FDA <font color="blue">clearances</font></td>
    </tr>
    <tr>
      <td>There is     a risk that the <font color="blue">proposed products</font> will be uneconomical to <font color="blue">manufacture</font> or     market or will not achieve <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>There is also a risk that     <font color="blue"><font color="blue">third parties</font> may</font> hold <font color="blue"><font color="blue">proprietary</font> rights</font> that <font color="blue">preclude us from marketing</font>     our <font color="blue">proposed products</font> or that <font color="blue">others will market</font> a superior or equivalent     product</td>
    </tr>
    <tr>
      <td>Further, our research and <font color="blue">development</font> <font color="blue">activities</font> might never result     in <font color="blue">commercially viable products</font></td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________                Our <font color="blue">product <font color="blue">candidates</font></font> are at the clinical and <font color="blue">preclinical stages</font> of     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Although several of our <font color="blue">product <font color="blue">candidates</font></font> have <font color="blue">demonstrated</font>     some promising results in early clinical (human) trials and preclinical     (animal) studies, they may not prove to be <font color="blue">effective</font> in humans</td>
    </tr>
    <tr>
      <td>For example,     <font color="blue">testing on animals may</font> occur <font color="blue">under different conditions than testing</font> in     people  and therefore the results of <font color="blue">animal studies</font> may not <font color="blue">accurately</font>     predict  human experience</td>
    </tr>
    <tr>
      <td>Likewise, <font color="blue">early clinical studies may</font> not be     predictive of <font color="blue">eventual safety</font> or <font color="blue">effective</font>ness results in larger-scale     <font color="blue">pivotal <font color="blue">clinical trials</font></font></td>
    </tr>
    <tr>
      <td>There are many <font color="blue">regulatory</font> steps that must be taken before any of these     <font color="blue">product <font color="blue">candidates</font></font> will be eligible for FDA approval and <font color="blue">subsequent sale</font>,     including the <font color="blue">completion</font> of preclinical and <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We do not     expect that these <font color="blue">product <font color="blue">candidates</font></font> will be <font color="blue">commercially available</font> for     <font color="blue">several years</font>, if ever</td>
    </tr>
    <tr>
      <td>We Are Uncertain Whether Additional Funding Will Be Available For Our Future     Capital Needs and Commitments          We will require substantial funds in addition to our existing working     capital to develop our <font color="blue">product <font color="blue">candidates</font></font> and otherwise to meet our business     <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">never generated sufficient revenue during</font> any period     since our inception to cover our expenses and have spent, and expect to     continue  to  spend,  substantial  funds  to continue our research and     <font color="blue">development</font> and <font color="blue">clinical programs</font></td>
    </tr>
    <tr>
      <td>Any one of the following factors, among     others, could cause us to require <font color="blue"><font color="blue">additional</font> funds</font> or otherwise cause our     <font color="blue">cash <font color="blue">requirements</font></font> in the future to <font color="blue">increase materially</font>:       •   results of research and <font color="blue">development</font> <font color="blue">activities</font>;         •   progress of our <font color="blue">preclinical studies</font> or <font color="blue">clinical trials</font>;         •   results of <font color="blue">clinical trials</font>;         •   changes in or <font color="blue">terminations</font> of our <font color="blue"><font color="blue"><font color="blue">relationship</font>s</font> with strategic</font>     partners;          •     changes in the focus, direction, or costs of our research and     <font color="blue">development</font> programs;         •   <font color="blue">competitive</font> and <font color="blue">technological advances</font>;         •   <font color="blue">establishment</font> of marketing and <font color="blue">sales capabilities</font>;         •   <font color="blue">manufacturing</font>;         •   the <font color="blue">regulatory</font> approval process; or         •   <font color="blue">product launch</font></td>
    </tr>
    <tr>
      <td>We Must Show the Safety and Efficacy of Our Product Candidates Through     Clinical Trials, the Results of Which Are Uncertain          Before obtaining <font color="blue">regulatory</font> approvals for the <font color="blue">commercial sale</font> of our     products, we must demonstrate, through <font color="blue">preclinical studies</font> (animal testing)     and <font color="blue">clinical trials</font> (human testing), that our <font color="blue">proposed products</font> are safe and     <font color="blue">effective</font>  for  use  in <font color="blue">each target indication</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials may</font> not <font color="blue">demonstrate sufficient safety</font> and efficacy to obtain     the required <font color="blue">regulatory</font> approvals or result in <font color="blue">marketable products</font></td>
    </tr>
    <tr>
      <td>The     failure to <font color="blue">adequately demonstrate</font> the safety and efficacy of a product under     <font color="blue">development</font> could delay or prevent <font color="blue">regulatory</font> approval of the potential     product</td>
    </tr>
    <tr>
      <td>Clinical trials for the <font color="blue">product <font color="blue">candidates</font></font> we are developing may be     <font color="blue">delayed by</font> many factors, including that <font color="blue">potential patients</font> for testing are     limited in number</td>
    </tr>
    <tr>
      <td>The failure of any <font color="blue">clinical trials</font> to <font color="blue">meet applicable</font>     <font color="blue">regulatory</font> standards could cause such trials to be delayed or terminated,     <font color="blue">which could further delay</font> the <font color="blue">commercialization</font> of                                         13       _________________________________________________________________           any of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Newly <font color="blue">emerging safety risks</font> observed in     animal or <font color="blue">human studies also</font> can result in delays of ongoing or proposed     <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">such delays</font> will increase</font> our product <font color="blue">development</font>     costs</td>
    </tr>
    <tr>
      <td>If <font color="blue">such delays</font> are <font color="blue">significant</font>, they <font color="blue">could negatively affect</font> our     financial results and the <font color="blue">commercial prospects</font> for our products</td>
    </tr>
    <tr>
      <td>Panzem^Ò NCD May Not be Successful          We have <font color="blue">reformulated</font> our <font color="blue">lead product candidate</font>, Panzem^Ò, in order to     increase  its  <font color="blue">concentration</font>  in  the blood stream</td>
    </tr>
    <tr>
      <td>Through the use of     NanoCrystal^® Colloidal Dispersion (NCD), a <font color="blue">proprietary</font> <font color="blue">technology</font> of Elan     Drug  Delivery,  Inc</td>
    </tr>
    <tr>
      <td>(“Elan”),  we  have <font color="blue">reformulated</font> Panzem^Ò as an     orally-administered liquid suspension</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2006, we commenced a     Phase 2 study using Panzem^Ò NCD in patients with <font color="blue">glioblastoma</font> multiforme     (GBM)</td>
    </tr>
    <tr>
      <td>Although Panzem^Ò NCD <font color="blue">showed increased levels</font> in the blood in <font color="blue">Phase     </font>1b <font color="blue">clinical trials</font>, it may not work as well in <font color="blue">upcoming trials as</font> it has in     <font color="blue">earlier testing</font></td>
    </tr>
    <tr>
      <td>We May Need New Collaborative Partners to Further Develop and Commercialize     Products, and if We Enter Into Such Arrangements, We May Give Up Control     Over the Development and Approval Process and Decrease Our Potential Revenue          We plan to develop and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> with or     <font color="blue">without corporate alliances</font> and partners</td>
    </tr>
    <tr>
      <td>Nonetheless, we intend to explore     <font color="blue">opportunities</font> for <font color="blue">new corporate alliances</font> and partners to help us develop,     <font color="blue">commercialize</font> and market our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We expect to grant to our     partners <font color="blue">certain rights</font> to <font color="blue">commercialize</font> any products developed under these     <font color="blue">agreements</font>,  and  we  <font color="blue">may rely on</font> our partners to <font color="blue">conduct research</font> and     <font color="blue">development</font> efforts and <font color="blue">clinical trials</font> on, obtain <font color="blue">regulatory</font> approvals for,     and <font color="blue">manufacture</font> and market any <font color="blue">products licensed</font> to them</td>
    </tr>
    <tr>
      <td>Each individual     <font color="blue">partner will seek</font> to control the amount and timing of <font color="blue">resources devoted</font> to     these  <font color="blue">activities</font> <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>We anticipate obtaining <font color="blue">revenues from</font> our     <font color="blue">strategic partners under such <font color="blue"><font color="blue">relationship</font>s</font></font> in the form of research and     <font color="blue">development</font> payments and <font color="blue">payments upon achievement</font> of <font color="blue">certain <font color="blue">milestones</font></font></td>
    </tr>
    <tr>
      <td>Since we <font color="blue">generally</font> expect to obtain a royalty for sales or a percentage of     profits of <font color="blue">products licensed</font> to <font color="blue">third parties</font>, our <font color="blue">revenues may</font> be less than     if we retained all <font color="blue">commercialization</font> rights and <font color="blue">marketed products directly</font></td>
    </tr>
    <tr>
      <td>In  addition,  there is a risk that our <font color="blue">corporate partners will pursue</font>     <font color="blue">alternative <font color="blue">technologies</font></font> or develop <font color="blue">competitive</font> products as a means for     developing <font color="blue">treatments</font> for the <font color="blue">diseases targeted by</font> our programs</td>
    </tr>
    <tr>
      <td>We  may  not  be  successful  in  <font color="blue">establishing</font>  any <font color="blue">collaborative</font>     <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Even if we do <font color="blue">establish such collaborations</font>, we may not     <font color="blue">successfully</font> <font color="blue">commercialize</font> any <font color="blue">products under</font> or derive any <font color="blue">revenues from</font>     these <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">strategy also involves entering into multiple</font>,     <font color="blue">concurrent <font color="blue">strategic alliances</font></font> to pursue <font color="blue">commercialization</font> of our core     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>There is a risk that we will be unable to <font color="blue">manage simultaneous</font>     programs  <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>With respect to existing and <font color="blue">potential future</font>     <font color="blue">strategic alliances</font> and <font color="blue">collaborative</font> <font color="blue">arrangements</font>, we <font color="blue">will <font color="blue">depend on</font></font> the     expertise and <font color="blue">dedication</font> of <font color="blue">sufficient resources by</font> these <font color="blue">outside parties</font> to     develop,  <font color="blue">manufacture</font>,  or <font color="blue">market products</font></td>
    </tr>
    <tr>
      <td>If a strategic alliance or     <font color="blue">collaborative</font> partner fails to develop or <font color="blue">commercialize</font> a product to which     it has rights, we may not recognize any revenues on that particular product</td>
    </tr>
    <tr>
      <td>We Have No Current Manufacturing or Marketing Capacity and Rely on Only One     Supplier For Some of Our Products          We do not expect to <font color="blue">manufacture</font> or <font color="blue">market products</font> in the near term,     but we may try to do so in <font color="blue">certain cases</font></td>
    </tr>
    <tr>
      <td>We do not currently have the     <font color="blue">capacity</font> to <font color="blue">manufacture</font> or <font color="blue">market products</font> and we have limited experience in     these  <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If we elect to perform these functions, we will be     required to either develop these <font color="blue">capacities</font>, or <font color="blue">contract with others</font> to     perform some or all of these tasks</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">dependent</font> to a <font color="blue">significant</font>     extent on corporate partners, licensees, or other entities for <font color="blue">manufacturing</font>     and  marketing  of products</td>
    </tr>
    <tr>
      <td>If we engage directly in <font color="blue">manufacturing</font> or     marketing, we will require substantial <font color="blue"><font color="blue">additional</font> funds</font> and personnel and     will be required to <font color="blue">comply with</font> extensive <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We may be unable to     develop  or  contract  for  these <font color="blue">capacities</font> when required to do so in     <font color="blue">connection with</font> our business</td>
    </tr>
    <tr>
      <td>We  are currently <font color="blue">manufacturing</font> products for <font color="blue">clinical trials</font> on a     contract  basis</td>
    </tr>
    <tr>
      <td>Panzem^Ò  NCD, our lead small molecule <font color="blue">clinical drug</font>     candidate, is currently <font color="blue">manufacture</font>d by Elan</td>
    </tr>
    <tr>
      <td>We do not have <font color="blue">arrangements</font> in     place <font color="blue">with <font color="blue">alternative suppliers</font></font> if our <font color="blue">current supplier</font> Elan was unable to     deliver the product in <font color="blue">necessary</font> quantities</td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________                We <font color="blue">depend on</font> our third-party <font color="blue">manufacture</font>rs to perform their <font color="blue">obligations</font>     <font color="blue">effective</font>ly and on a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">third parties</font> may</font> not meet their     <font color="blue">obligations</font> and any such non-performance may delay clinical <font color="blue">development</font> or     submission of products for <font color="blue">regulatory</font> approval, or <font color="blue">otherwise impair</font> our     <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> problem experienced by one of our     <font color="blue">suppliers could</font> result in a delay or <font color="blue">interruption</font> in the supply of materials     to <font color="blue">us until such supplier resolves</font> the problem or an <font color="blue">alternative source</font> of     supply is located</td>
    </tr>
    <tr>
      <td>Any delay or <font color="blue">interruption</font> would likely lead to a delay or     <font color="blue">interruption</font> of <font color="blue">manufacturing</font> <font color="blue">operations</font>, which <font color="blue">could negatively affect</font> our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Although we have identified <font color="blue">alternative suppliers</font> for our     product  <font color="blue">candidates</font>,  we  have  not  <font color="blue">entered into contractual</font> or other     <font color="blue">arrangements</font> with them</td>
    </tr>
    <tr>
      <td>If we needed to use an <font color="blue">alternate supplier</font> for any     product, we would experience <font color="blue">delays while</font> we negotiated an <font color="blue">agreement with</font>     them for the <font color="blue">manufacture</font> of <font color="blue">such product</font></td>
    </tr>
    <tr>
      <td>In addition, we may be unable to     negotiate <font color="blue">manufacturing</font> terms with a <font color="blue">new supplier</font> that are as favorable as     the terms we have with our <font color="blue">current supplier</font>s</td>
    </tr>
    <tr>
      <td>Problems with any <font color="blue">manufacturing</font> processes could result in product     defects, which could require us to <font color="blue">delay shipment</font> of products or recall     <font color="blue">products previously shipped</font></td>
    </tr>
    <tr>
      <td>In addition, any prolonged <font color="blue">interruption</font> in the     <font color="blue">operations</font>  of  the <font color="blue">manufacturing</font> <font color="blue">facilities</font> of one of our sole-source     <font color="blue">suppliers could</font> result in the <font color="blue">cancellation</font> of shipments</td>
    </tr>
    <tr>
      <td>A number of factors     could cause <font color="blue">interruption</font>s, including <font color="blue">equipment malfunctions</font> or failures, or     damage to a <font color="blue"><font color="blue">facility</font> due</font> to <font color="blue">natural disasters</font> or otherwise</td>
    </tr>
    <tr>
      <td>Because our     <font color="blue">manufacturing</font> processes are or are expected to be <font color="blue">highly complex</font> and subject     to a lengthy FDA approval process, alternative qualified production <font color="blue">capacity</font>     may not be <font color="blue">available on</font> a <font color="blue">timely basis</font> or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Difficulties </font>or delays in     our <font color="blue">manufacturing</font> could increase our costs and damage our reputation</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of <font color="blue">pharmaceutical products</font> can be an expensive, time     consuming, and <font color="blue">complex process</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>often encounter <font color="blue">difficult</font>ies     in scaling-up production of <font color="blue">new products</font>, including <font color="blue">quality control</font> and     assurance and shortages of personnel</td>
    </tr>
    <tr>
      <td>Delays in <font color="blue">formulation</font> and scale-up to     commercial quantities could result in <font color="blue">additional</font> expense and delays in our     <font color="blue">clinical trials</font>, <font color="blue">regulatory</font> <font color="blue">submissions</font>, and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Failure of Manufacturing Facilities Producing Our Product Candidates to     Maintain Regulatory Approval Could Delay or Otherwise Hinder Our Ability to     Market Our Product Candidates          Any  <font color="blue">manufacture</font>r  of  our  <font color="blue">product <font color="blue">candidates</font></font> will be subject to     applicable Good Manufacturing Practices (GMP) <font color="blue">prescribed by</font> the FDA or other     rules and <font color="blue">regulations</font> <font color="blue">prescribed by</font> foreign <font color="blue">regulatory</font> authorities</td>
    </tr>
    <tr>
      <td>We and     any  of  our  <font color="blue">collaborators</font>  may  be  unable to enter into or maintain     <font color="blue"><font color="blue">relationship</font>s</font>  either  <font color="blue">domestically</font> or abroad with <font color="blue">manufacture</font>rs whose     <font color="blue">facilities</font> and procedures comply or will continue to <font color="blue">comply with</font> GMP and who     are  able to produce our small molecules in <font color="blue">accordance with applicable</font>     <font color="blue">regulatory</font> standards</td>
    </tr>
    <tr>
      <td>Failure by a <font color="blue">manufacture</font>r of our products to comply     with GMP could result in <font color="blue">significant</font> time delays or our <font color="blue">inability</font> to obtain     <font color="blue">marketing approval</font> or, should we have <font color="blue">market approval</font>, for <font color="blue">such approval</font> to     continue</td>
    </tr>
    <tr>
      <td>Changes in our <font color="blue">manufacture</font>rs could require new product testing and     <font color="blue">facility</font> compliance <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td>In the United States, failure to comply     with GMP or other <font color="blue">applicable legal <font color="blue">requirements</font></font> can lead to <font color="blue">federal seizure</font>     of violated products, injunctive actions brought by the <font color="blue">federal government</font>,     <font color="blue">inability</font> to <font color="blue">export product</font>, and <font color="blue">potential criminal</font> and <font color="blue">civil <font color="blue">liability</font> on</font>     the part of a company and its officers and employees</td>
    </tr>
    <tr>
      <td>Manufacturing Our Product Candidates May Not Be Commercially Feasible          The <font color="blue">manufacturing</font> processes for several of the small molecules we are     developing have not <font color="blue">yet been tested at commercial levels</font>, and it may not be     possible to <font color="blue">manufacture</font> these materials in a cost-<font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td>We  Depend  on Patents and Other Proprietary Rights, Some of Which are     Uncertain          Our <font color="blue">success will depend</font> in part on our ability to obtain patents for     our products, both in the <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of     bio<font color="blue">technology</font> and <font color="blue">pharmaceutical companies</font> in general is <font color="blue">highly uncertain</font>     and <font color="blue">involves complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>Risks that relate to     patenting our products include the following:                                         15       _________________________________________________________________             •   our failure to obtain <font color="blue">additional</font> patents;         •   challenge, invalidation, or <font color="blue">circumvention</font> of <font color="blue">patents already issued</font> to     us;         •   failure of the <font color="blue">rights granted under</font> our patents to <font color="blue">provide sufficient</font>     protection;         •   in<font color="blue">dependent</font> <font color="blue">development</font> of similar products by <font color="blue">third parties</font>; or          •   ability of <font color="blue">third parties</font> to <font color="blue">design around patents issued</font> to our     <font color="blue">collaborators</font> or us</td>
    </tr>
    <tr>
      <td>For several of the products that we are developing, including Panzem^®,     <font color="blue">composition</font> of matter patents are not available because the compounds are in     the <font color="blue">public domain</font></td>
    </tr>
    <tr>
      <td>In these cases, only patents covering the “use” of the     product are available</td>
    </tr>
    <tr>
      <td>In general, patents covering a new use for a known     compound can be more <font color="blue">difficult</font> to <font color="blue">enforce against infringers</font> of the use     claims in the patent</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">potential products</font> may conflict with patents</font> that have been or may     be granted to competitors, universities or others</td>
    </tr>
    <tr>
      <td>As the bio<font color="blue">technology</font>     industry expands and more patents are issued, the risk increases that our     <font color="blue">potential products</font> may give rise to claims that may infringe the patents of     others</td>
    </tr>
    <tr>
      <td>Such other persons could bring legal actions against us claiming     damages and seeking to enjoin <font color="blue">clinical testing</font>, <font color="blue">manufacturing</font> and marketing     of the <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">such litigation could</font> result in substantial     cost  to  us  and  diversion of <font color="blue">effort by</font> our <font color="blue">management</font> and technical     personnel</td>
    </tr>
    <tr>
      <td>If any of these actions are successful, in addition to any     <font color="blue">potential <font color="blue">liability</font></font> for damages, we could be required to obtain a license in     order to continue to <font color="blue">manufacture</font> or market the <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>We may not     prevail in any action and any license required under any needed <font color="blue">patent might</font>     not be made <font color="blue">available on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>We are a party to sponsored research <font color="blue">agreements</font> and license <font color="blue">agreements</font>     that  require us to make <font color="blue">milestone payments upon attainment</font> of certain     <font color="blue">regulatory</font> <font color="blue">milestones</font></td>
    </tr>
    <tr>
      <td>Failure to meet such <font color="blue">milestones</font> could result in the     loss of <font color="blue">certain rights</font> to compounds covered under such license <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">also rely on trade secret protection</font> for our <font color="blue">confidential</font> and     <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>However, <font color="blue">trade secrets</font> are <font color="blue">difficult</font> to protect and     others  may in<font color="blue">dependent</font>ly develop substantially equivalent <font color="blue">proprietary</font>     information and <font color="blue">techniques</font> and <font color="blue">gain access</font> to our <font color="blue">trade secrets</font> and disclose     our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">meaningfully protect</font> our rights to     unpatented  trade  secrets</td>
    </tr>
    <tr>
      <td>We  require  our  employees  to  complete     <font color="blue">confidential</font>ity training that specifically addresses <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>All     employees,  <font color="blue">consultants</font>,  and  advisors  are  required  to  execute  a     <font color="blue">confidential</font>ity agreement when beginning an <font color="blue">employment</font> or a consulting     <font color="blue">relationship</font>  with us</td>
    </tr>
    <tr>
      <td>The <font color="blue">agreements</font> <font color="blue">generally</font> provide that all trade     secrets and <font color="blue">inventions</font> conceived by the individual and all <font color="blue">confidential</font>     information developed or made known to the individual during the term of the     <font color="blue">relationship</font> automatically become our <font color="blue">exclusive property</font></td>
    </tr>
    <tr>
      <td><font color="blue">Employees </font>and     <font color="blue">consultants</font> must keep such information <font color="blue">confidential</font> and may not disclose     such  information  to <font color="blue">third parties</font> except in specified <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue">agreements</font> may not <font color="blue">provide meaningful protection</font> for our     <font color="blue">proprietary</font> information in the event of <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> of     such information</td>
    </tr>
    <tr>
      <td>To the extent that <font color="blue">consultants</font>, key employees, or other <font color="blue">third parties</font>     <font color="blue">apply technological</font> information in<font color="blue">dependent</font>ly developed by them or by others     to our proposed projects, <font color="blue">disputes may</font> arise as to the <font color="blue"><font color="blue">proprietary</font> rights</font> to     such  information</td>
    </tr>
    <tr>
      <td>Any such <font color="blue">disputes may</font> not be resolved in our favor</td>
    </tr>
    <tr>
      <td>Certain of our <font color="blue">consultants</font> are employed by or have consulting <font color="blue">agreements</font>     with other companies and any <font color="blue">inventions</font> discovered by them <font color="blue">generally</font> will     not become our property</td>
    </tr>
    <tr>
      <td>Our Potential Products Are Subject to Government Regulatory Requirements and     an Extensive Approval Process          Our  research,  <font color="blue">development</font>,  preclinical  and  clinical  trials,     <font color="blue">manufacturing</font>, and marketing of most of our <font color="blue">product <font color="blue">candidates</font></font> are subject     to an extensive <font color="blue">regulatory</font> approval process by the FDA and other <font color="blue">regulatory</font>     agencies in the <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td>The process of obtaining FDA and     other  required  <font color="blue">regulatory</font>  approvals for drug and biologic products,     including required preclinical and <font color="blue">clinical testing</font>, is time consuming and     expensive</td>
    </tr>
    <tr>
      <td>Even after                                         16       _________________________________________________________________           spending  time  and money, we may not receive <font color="blue">regulatory</font> approvals for     <font color="blue">clinical testing</font> or for the <font color="blue">manufacturing</font> or marketing of any products</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">collaborators</font> or we may encounter <font color="blue">significant</font> delays or costs in the effort     to secure <font color="blue">necessary</font> approvals or licenses</td>
    </tr>
    <tr>
      <td>Even if we obtain <font color="blue">regulatory</font>     clearance for a product, that <font color="blue">product will</font> be subject to <font color="blue">continuing review</font></td>
    </tr>
    <tr>
      <td>Later <font color="blue">discovery</font> of <font color="blue">previously unknown defects</font> or failure to <font color="blue">comply with</font> the     applicable  <font color="blue">regulatory</font>  <font color="blue">requirements</font>  may  result in <font color="blue">restrictions on</font> a     product’s marketing or withdrawal of the <font color="blue">product from</font> the market, as well as     <font color="blue">possible civil</font> or <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>Potential Products May Subject Us to Product Liability for Which Insurance     May Not Be Available          The use of our <font color="blue">potential products</font> in <font color="blue">clinical trials</font> and the marketing     of any <font color="blue">pharmaceutical products</font> may expose us to <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>We     have obtained a level of <font color="blue"><font color="blue">liability</font> <font color="blue">insurance coverage</font></font> that we believe is     adequate  in  scope and coverage for our <font color="blue">current stage</font> of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>However, our <font color="blue">present <font color="blue">insurance coverage</font> may</font> not be adequate to <font color="blue">protect us</font>     <font color="blue">from <font color="blue">liabilities</font></font> we <font color="blue">might incur</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">existing coverage will</font> not     be <font color="blue">adequate as</font> we further develop products and, in the future, adequate     <font color="blue">insurance coverage</font> and indemnification by <font color="blue">collaborative</font> partners may not be     available  in <font color="blue">sufficient amounts</font> or at a <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>If a product     <font color="blue">liability</font> claim or series of claims are brought against us for uninsured     <font color="blue">liabilities</font>, or in excess of our <font color="blue">insurance coverage</font>, the payment of such     <font color="blue">liabilities</font> could have a negative effect on our business and financial     condition</td>
    </tr>
  </tbody>
</table>